

AMENDMENTS TO EXISTING LICENSES ISSUED (continued):

Throughout TX	Proportional Technologies Inc.	L04747	Houston	33	11/10/17
Throughout TX	Sentinel Integrity Solutions Inc.	L06735	Houston	02	11/09/17
Throughout TX	American Piping Inspection Inc.	L06835	Kilgore	06	11/07/17
Throughout TX	Tri-Point Oil & Gas Production Systems L.L.C.	L06897	Kountze	01	11/01/17
Throughout TX	Shared Medical Services Inc.	L06142	Nacogdoches	23	11/06/17
Throughout TX	Tracerco	L03096	Pasadena	99	11/02/17
Throughout TX	Texas Oncology P.A.	L06759	San Antonio	05	11/06/17
Throughout TX	Hunter Industries Ltd.	L04175	San Marcos	12	11/13/17

RENEWAL OF LICENSES ISSUED:

Location of Use/Possession of Material	Name of Licensed Entity	License Number	City of Licensed Entity	Amendment Number	Date of Action
Austin	St. David's Healthcare Partnership L.P., L.L.P. dba St. David's North Austin Medical Center	L04910	Austin	102	11/14/17
Beaumont	The Goodyear Tire & Rubber Company	L06063	Beaumont	05	11/13/17
Brenham	Scott & White Hospital Brenham dba Baylor Scott & White Medical Center – Brenham	L03419	Brenham	36	11/01/17
Crowley	Aztec Manufacturing Partnership Ltd. dba Azz Tubular Products	L06080	Crowley	02	11/14/17
Duncanville	Afridi Heart Care P.A.	L06005	Duncanville	14	11/14/17
Irving	Columbia Medical Center of Las Colinas Inc. dba Medical City Las Colinas	L05084	Irving	25	11/07/17
Pasadena	University Cancer Center of Huntsville/Brenham Inc.	L06070	Pasadena	09	11/13/17
Pharr	Harish Koolwal M.D., P.A.	L05149	Pharr	14	11/14/17
San Antonio	VHS San Antonio Imaging Partners L.P. dba Baptist M&S Imaging Center	L04506	San Antonio	96	11/08/17
Throughout TX	Southern Services Inc. dba Southern Technical Services	L05270	Lake Jackson	63	11/14/17
Throughout TX	Techwell Surveys Corporation	L06089	Odessa	01	11/13/17

TERMINATIONS OF LICENSES ISSUED:

Location of Use/Possession of Material	Name of Licensed Entity	License Number	City of Licensed Entity	Amendment Number	Date of Action
Longview	The Good Shepherd Hospital Inc. dba Christus Good Shepherd Medical Center – Longview	L02411	Longview	100	11/07/17
Lubbock	Covenant Health System dba Joe Arrington Cancer Center	L04881	Lubbock	70	11/14/17
San Antonio	Bakthavathsalam Athreya M.D., P.A. & Associates	L06363	San Antonio	01	11/13/17
Throughout TX	IOS/PCI L.L.C.	L06790	Houston	03	11/09/17

TRD-201704982
 Barbara L. Klein
 Interim General Counsel
 Department of State Health Services
 Filed: December 6, 2017



Order Placing AB-CHMINACA, AB-PINACA and THJ-2201 into Schedule I

The Administrator of the Drug Enforcement Administration (DEA) issued a final rule placing N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other names: "AB-CHMINACA"); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (Other names:

"AB-PINACA"); and [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (Other names: "THJ-2201") into Schedule I pursuant to the scheduling provisions of the of the United States Controlled Substances Act (CSA). The final rule was published in the *Federal Register*, Volume 82, Number 198, pages 47971-47974. This action was based on the following:

1. THJ-2201, AB-PINACA and AB-CHMINACA have a high potential for abuse that is comparable to other schedule I substances such as delta-9-tetrahydrocannabinol and JWH-0108;
2. THJ-2201, AB-PINACA and AB-CHMINACA have no currently accepted medical use in treatment in the United States; and
3. There is a lack of accepted safety for use of THJ-2201, AB-PINACA and AB-CHMINACA under medical supervision.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the *Federal Register*. In the capacity as the Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substances THJ-2201, AB-PINACA and AB-CHMINACA be placed into Schedule I.

SCHEDULES

Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated.

SCHEDULE I

--Schedule I hallucinogenic substances

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of the substance's salts, isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this Schedule I hallucinogenic substances section only, the term "isomer" includes optical, position, and geometric isomers):

*(70) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other names: "AB-CHMINACA");

*(71) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (Other names: "AB-PINACA"); and

*(72) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (Other names: "THJ-2201").

Changes are denoted by an asterisk *.

TRD-201704981

Barbara L. Klein

Interim General Counsel

Department of State Health Services

Filed: December 6, 2017



Order Temporarily Adding Ortho-Fluorofentanyl, Tetrahydrofuranlyl Fentanyl, Methoxyacetyl Fentanyl and FUB-AMB into Schedule I

The Administrator of the Drug Enforcement Administration issued a temporary scheduling order to schedule the synthetic opioids N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide,

its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other names: "ortho-fluorofentanyl, 2-fluorofentanyl"); N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: "tetrahydrofuranlyl fentanyl"); and 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: "methoxyacetyl fentanyl") into Schedule I of the Controlled Substances Act effective October 26, 2017. This temporary scheduling order was published in the October 26, 2017, issue of the *Federal Register*, Volume 82, Number 206, pages 49504-49508. The Administrator has taken action based on the following.

1. Ortho-fluorofentanyl, tetrahydrofuranlyl fentanyl, and methoxyacetyl fentanyl have a high potential for abuse.
2. Ortho-fluorofentanyl, tetrahydrofuranlyl fentanyl, and methoxyacetyl fentanyl have no current accepted medical use in treatment in the United States.
3. There is a lack of accepted safety for use under medical supervision for ortho-fluorofentanyl, tetrahydrofuranlyl fentanyl, and methoxyacetyl fentanyl.
4. Control of ortho-fluorofentanyl, tetrahydrofuranlyl fentanyl, and methoxyacetyl fentanyl is necessary to avoid an imminent hazard to the public safety.

The Administrator of the Drug Enforcement Administration issued a temporary scheduling order to schedule the synthetic cannabinoid methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: "FUB-AMB, MMB-FUBINACA, AMB-FUBINACA") into Schedule I of the Controlled Substances Act effective November 3, 2017. This temporary scheduling order was published in the November 3, 2017, issue of the *Federal Register*, Volume 82, Number 212, pages 51154-51158. The Administrator has taken action based on the following.

1. FUB-AMB has a high potential for abuse.
2. FUB-AMB has no current accepted medical use in treatment in the United States.
3. There is a lack of accepted safety for use under medical supervision for FUB-AMB.
4. Control of FUB-AMB is necessary to avoid an imminent hazard to the public safety.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the *Federal Register*. In the capacity as the Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substances ortho-fluorofentanyl, tetrahydrofuranlyl fentanyl, methoxyacetyl fentanyl, and FUB-AMB be placed into Schedule I temporarily listed substances.

SCHEDULE I

--Schedule I temporarily listed substances subject to emergency scheduling by the United States Drug Enforcement Administration.

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's salts, esters, ethers, isomers, optical isomers, positional isomers, geometric isomers and salts of isomers, esters, and ethers if the existence of the salts, isomers, esters, ethers and salts of isomers, esters and ethers is possible within the specific chemical designation.

*14. N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (Other names: "ortho-fluorofentanyl, 2-fluorofentanyl");

*15. N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (Other name: "tetrahydrofuranfentanyl");

*16. 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its isomers, esters, ethers, salts and salts of isomers, esters and ethers (Other name: "methoxyacetyl fentanyl"); and

*17. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Other names: "FUB-AMB, MMB-FUBINACA, AMB-FUBINACA").

Changes to the schedules are marked with an asterisk *.

TRD-201704980

Barbara L. Klein

Interim General Counsel

Department of State Health Services

Filed: December 6, 2017

◆ ◆ ◆
University of Houston System

Business and Service Review of Pouring Rights

The University of Houston System announces a Request for Proposal (RFP) for consultant services pursuant to Government Code, Chapter 2254, Subchapter B.

RFP783-18005, Business and Service Review of Pouring Rights Contract

Purpose:

The University of Houston System (UHS) Auxiliary Services is seeking competitive responses to a Request for Proposal ("RFP") for a Consultant to provide an independent analysis of its pouring rights and beverage vending contract that incorporates industry best practices and creative solutions that will meet the System's complex needs.

Eligible Applicants:

Consulting firms with related knowledge and experience in:

Firms that have expertise with evaluating pouring rights and beverage vending contracts.

Services to be performed:

* an independent, comprehensive evaluation of the System pouring rights and beverage vending contract

* guidance and assistance in any potential service and technology enhancements related to the pouring rights and beverage contract management

* guidance to the System regarding the business operations of this contract, including a review of contract oversight, such as commission reconciliations, accounting practices, and contract management relative to current terms in the agreement

* development of a comprehensive five year business plan and pro forma for the business operation of the pouring rights contract development of performance indicators that can be used to monitor contract performance from a university perspective and be easily incorporated into our contract management software

* guidance for management policies, procedures, and systems, including support in the event of a potential re-bidding of the System pouring rights and beverage vending contract recommendations to the System

including advice to future contract length and terms, as well as financial and operational advice related to this agreement and its oversight.

Finding by Chief Executive Officer, Renu Khator:

After reviewing the current status and discussing this matter with the staff, the evaluation of these services can only be conducted by a firm considered expert in pouring rights and beverage vending contracts. The university believes that using a third-party consultant, who has conducted similar evaluations for universities similar in context and size to universities within the UH System, will provide the System with best practices that can be used to improve the service to our customers. The expertise needed for this evaluation is complex and requires a comprehensive knowledge of national industry trends related to pouring rights agreements. Currently, the Auxiliary Services staff does not have the expertise to complete this evaluation. Thus, it is necessary for the System to engage a consultant to advise it regarding its pouring rights contract and management of this contract, and make recommendations, as appropriate for the improvement of this program.

Review and Award Criteria:

All proposals will be evaluated by appointed representatives of the University in accordance with the following procedures:

Purchasing will receive and review each RFP proposal to ensure it meets the requirements of the RFP. Qualified proposals will be given to the selection committee.

Each member of the selection committee will independently evaluate the qualified proposals according to the criteria in section IX of the RFP, except for price, and send their evaluations to Purchasing. Price will be evaluated by Project Manager.

Purchasing will combine the committee's scores to determine which proposal received the highest combined score.

Purchasing will notify the respondent with the highest score that the University intends to contract with them.

Deadlines: UH must receive proposals according to instructions in the RFP package on or before Tuesday, January 16, 2018, at 2:00 p.m. CDT and the HUB Subcontracting Plan (HSP) on or before Wednesday, January 17, 2018, at 2:00 p.m. CDT.

Obtaining a copy of the RFP: Copies will be available on the Electronic State Business Daily (ESBD) at <http://www.txsmartbuy.com/sp>.

The sole point of contact for inquiries concerning RFP is:

Jack Tenner

UH Purchasing

5000 Gulf Freeway, ERP 1, Rm.204

Houston, Texas 77204-5015

Phone: (713) 743-5671

Email: jdtenner@central.uh.edu

TRD-201704875

Jackie D. Tenner

Director of Purchasing

University of Houston System

Filed: December 1, 2017

◆ ◆ ◆
Texas Department of Insurance

Company Licensing